SCHEMBL23817980

SCHEMBL23817980

COC(=O)CN1CCOc2cc(N(CCC#N)C(=O)CCl)ccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FEM1B Q9UK73 3/20 0.62
▸ FNIP1 Q8TF40 1/20 0.62
▸ ALDH1A1 P00352 7/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ BRD4 O60885 2/20 0.47
▸ HTT P42858 3/20 0.45
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ MAPT P10636 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30132888 1.00 FEM1B (0.62) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL23817965 0.90 FEM1B (0.59) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL23804993 0.89 FEM1B (0.67) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL25455734 0.87 FEM1B (0.60) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL23818425 0.84 FEM1B (0.57) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL25455179 0.82 FEM1B (0.48) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL23817933 0.82 FEM1B (0.48) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL25171623 0.82 FEM1B (0.68) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL23804989 0.81 FEM1B (0.61) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL30132890 0.81 FEM1B (0.61) FEM1BFNIP1ALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148299-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-11 — — US disclosed
US-20230148299-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-11 — — US disclosed
US-20230148299-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-11 — — US disclosed
CN-115666538-A FEM1B protein binding agents and uses thereof 加利福尼亚大学董事会 2023-01-31 — — CN disclosed
WO-2021183431-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148299-A1 FEM1B PROTEIN BINDING AGENTS AND USES THEREOF FEM1B, GSKIP, FNIP1 FEM1B 1/4885FNIP1 3/4885ALDH1A1 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback